Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture, Mol. Pharmacol, vol.44, pp.707-715, 1993. ,
Signalling pathways of the TNF superfamily: a double-edged sword, Nat. Rev. Immunol, vol.3, p.745, 2003. ,
Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P4502C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes, Drug Metab. Dispos. Biol. Fate Chem, vol.35, pp.1687-1693, 2007. ,
Regulation of Drug-Metabolizing Enzymes and Transporters in Inflammation, Annu. Rev. Pharmacol. Toxicol, vol.46, pp.123-149, 2006. ,
Pathogen Recognition and Innate Immunity, Cell, vol.124, pp.783-801, 2006. ,
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial, Haematologica, vol.101, pp.1065-1073, 2016. ,
Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis, J. Exp. Pharmacol, vol.10, pp.9-17, 2018. ,
Catecholamines induce an inflammatory response in human hepatocytes, Crit. Care Med, vol.36, pp.848-854, 2008. ,
Sodium-dependent bile salt transporters of the SCL10A Transporter Family: More than solute transporters, Pflugers Arch, p.466, 2014. ,
The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, 2016. ,
, JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects, vol.77, pp.521-546, 2017.
Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation, Hematol. Oncol. Stem Cell Ther, 2019. ,
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms, J. Cell. Mol. Med, vol.17, pp.1385-1396, 2013. ,
Macrophage polarization and plasticity in health and disease, Immunol. Res, vol.53, pp.11-24, 2012. ,
C-reactive Protein, J. Biol. Chem, vol.279, pp.48487-48490, 2004. ,
Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites, Nat. Commun, vol.8, 2017. ,
Regulation of tumour necrosis factor signalling: live or let die, Nat. Rev. Immunol, vol.15, pp.362-374, 2015. ,
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628), 2018. ,
The Myeloproliferative Disorders, N. Engl. J. Med, vol.355, pp.2452-2466, 2006. ,
Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling, 2017. ,
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer, Clin. Breast Cancer, vol.18, pp.1205-1215, 2018. ,
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors, J. Cell. Mol. Med, vol.17, pp.1397-1409, 2013. ,
Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein, Eur. J. Clin. Pharmacol, vol.72, pp.1413-1414, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01834388
The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways, Cell Death Differ, vol.24, pp.1153-1159, 2017. ,
Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance, J. Clin. Pharmacol, vol.58, pp.849-863, 2018. ,
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases, Nat. Rev. Rheumatol, vol.13, pp.217-233, 2017. ,
Rip1 Mediates the Trif-dependent Toll-like Receptor 3-and 4-induced NF-?B Activation but Does Not Contribute to Interferon Regulatory Factor 3 Activation, J. Biol. Chem, vol.280, pp.36560-36566, 2005. ,
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations ?, J. Pers. Med, vol.8, 2017. ,
Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters, Brain. Behav. Immun, vol.70, pp.61-75, 2018. ,
Lipopolysaccharide Clearance, Bacterial Clearance, and Systemic Inflammatory Responses Are Regulated by Cell Type-Specific Functions of TLR4 during Sepsis, J. Immunol. Author Choice, vol.190, pp.5152-5160, 2013. ,
Consequences of the disease-related L78R mutation for dimerization and activity of STAT3, J. Cell Sci, vol.127, pp.1899-1910, 2014. ,
IL-27 inhibits the TGF-?1-induced epithelial-mesenchymal transition in alveolar epithelial cells, BMC Cell Biol, vol.17, 2016. ,
Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism, Drug Metab. Rev, vol.46, pp.261-282, 2014. ,
Structural Complementarity of Toll/Interleukin-1 Receptor Domains in Toll-like Receptors and the Adaptors Mal and MyD88, J. Biol. Chem, vol.278, pp.41443-41451, 2003. ,
Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis, Mol. Cancer Res. molcanres, p.916, 2018. ,
, , p.4, 2014.
, Dimerization and Trans-autophosphorylation are Induced by Myddosome Assembly, Mol. Cell, vol.55, pp.891-903
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018, Blood Cancer J, vol.8, 2018. ,
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction, Nature, vol.413, p.78, 2001. ,
IKK? and TBK1 are essential components of the IRF3 signaling pathway, Nat. Immunol, vol.4, p.491, 2003. ,
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis, Arthritis Rheumatol. Hoboken NJ, vol.67, pp.334-343, 2015. ,
Acute-Phase Proteins and Other Systemic Responses to Inflammation, N. Engl. J. Med, vol.340, pp.448-454, 1999. ,
The Interleukin-1 Family: Back to the Future, Immunity, vol.39, pp.1003-1018, 2013. ,
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation, Clin. Lung Cancer, vol.19, pp.567-574, 2018. ,
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages, Science, vol.330, pp.841-845, 2010. ,
Off-Target Effects of BCR-ABL and JAK2 Inhibitors, Am. J. Clin. Oncol, vol.39, pp.76-84, 2016. ,
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial, Ann. Hematol, vol.97, pp.1591-1600, 2018. ,
Thromboembolic events in polycythemia vera, Ann. Hematol, vol.98, pp.1071-1082, 2019. ,
Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells, Int. J. Mol. Med, vol.38, pp.903-911, 2016. ,
THE SLCO (FORMER SLC21) SUPERFAMILY OF TRANSPORTERS, Mol. Aspects Med, vol.34, pp.396-412, 2013. ,
Chapter Eight -Interferon Beta: From Molecular Level to Therapeutic Effects, In International Review of Cell and Molecular Biology, pp.343-372, 2016. ,
Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata, J. Am. Acad. Dermatol, vol.74, pp.370-371, 2016. ,
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, N. Engl. J. Med, vol.366, pp.787-798, 2012. ,
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis, Leukemia, vol.30, pp.1701-1707, 2016. ,
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial, 2017. ,
Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice, Int. Immunopharmacol, vol.1, pp.189-199, 2001. ,
The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms, Chem. Biol. Interact, vol.220, pp.116-127, 2014. ,
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, vol.122, pp.1192-1202, 2013. ,
, , 2002.
IL)-11 AND IL-8 IN POLYCYTHAEMIA VERA, Cytokine, vol.20, pp.178-183 ,
, Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01402440
Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences, Biochimie, vol.96, pp.121-129, 2014. ,
Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages, J. Exp. Med, vol.209, pp.1167-1181, 2012. ,
TIRAP: an adapter molecule in the Toll signaling pathway, Nat. Immunol, vol.2, p.835, 2001. ,
Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC, Apoptosis Int. J. Program. Cell Death, vol.19, pp.1627-1636, 2014. ,
IL-6 as a keystone cytokine in health and disease, Nat. Immunol, vol.16, pp.448-457, 2015. ,
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies, Invest. New Drugs, vol.36, pp.683-695, 2018. ,
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed, J. Clin. Oncol, vol.33, pp.4039-4047, 2015. ,
Clinically relevant drug interactions with multikinase inhibitors: a review, Ther. Adv. Med. Oncol, vol.11, 2019. ,
, , 2018.
, Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials, Immunotherapy, vol.10, pp.391-402
Pillars Article: Approaching the Asymptote? Evolution and Revolution in Immunology, Cold Spring Harb Symp Quant Biol, vol.54, pp.4475-4487, 1989. ,
Drugs and hepatic transporters: A review, Pharmacol. Res, 2019. ,
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6, AAPS J, vol.18, pp.767-776, 2016. ,
The role of the liver in the response to LPS: experimental and clinical findings, J. Endotoxin Res, vol.8, pp.319-327, 2002. ,
Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol, vol.15, pp.234-248, 2018. ,
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B, J. Am. Acad. Dermatol, vol.78, pp.1205-1207, 2018. ,
Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved, FASEB J, vol.16, pp.1799-1801, 2002. ,
?-catenin and IL-1? dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis, Hepatol. Baltim. Md, vol.67, pp.1903-1919, 2018. ,
Phosphoinositide-Mediated Adaptor Recruitment Controls Toll-like Receptor Signaling, Cell, vol.125, pp.943-955, 2006. ,
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-?, Nat. Immunol, vol.9, pp.361-368, 2008. ,
Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation, PLoS ONE, vol.12, 2017. ,
TAB2 and TAB3 Activate the NF-?B Pathway through Binding to Polyubiquitin Chains, Mol. Cell, vol.15, pp.535-548, 2004. ,
Role of the Akt pathway in mRNA translation of interferonstimulated genes, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.4808-4813, 2008. ,
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol, vol.11, pp.373-384, 2010. ,
The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms, Haematologica, vol.100, pp.348-350, 2015. ,
Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor, Oncol. Lett, vol.17, pp.3981-3989, 2019. ,
Interleukin-6 and cytochrome-P450, reason for concern?, Rheumatol. Int, vol.32, pp.2601-2604, 2012. ,
Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis, Cell Stem Cell, vol.21, pp.489-501, 2017. ,
The SLC22 family with transporters of organic cations, anions and zwitterions, Mol. Aspects Med, vol.34, pp.413-435, 2013. ,
Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo, 2017. ,
The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis, Pharmacogenomics J, vol.18, p.760, 2018. ,
Interleukin-1? stimulates acute phase response and C-reactive protein synthesis by inducing an NF?B-and C/EBP?-dependent autocrine interleukin-6 loop, Mol. Immunol, vol.45, pp.2678-2689, 2008. ,
Genetic contribution to variable human CYP3A-mediated metabolism, Adv. Drug Deliv. Rev, vol.54, pp.1271-1294, 2002. ,
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis, Clin. Pharmacokinet, vol.56, pp.607-615, 2017. ,
Hepatocyte toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression, Exp. Mol. Med, vol.49, p.408, 2017. ,
STATs: transcriptional control and biological impact, Nat. Rev. Mol. Cell Biol, vol.3, p.651, 2002. ,
Role of solute carriers in response to anticancer drugs, Mol. Cell. Ther, vol.2, 2014. ,
Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer, Oncol. Rep, vol.41, pp.437-446, 2019. ,
Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells, Mol. Med. Rep, vol.17, pp.5581-5588, 2018. ,
, Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling, vol.465, pp.885-890, 2010.
LS104, a non-ATP-competitive smallmolecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells, Mol. Cancer Ther, vol.7, pp.1176-1184, 2008. ,
Role of Toll-Like Receptors in Changes in Gene Expression and NF-?B Activation in Mouse Hepatocytes Stimulated with Lipopolysaccharide, Infect. Immun, vol.70, pp.3433-3442, 2002. ,
, MACROPHAGE RECRUITMENT BY FIBROCYSTIN-DEFECTIVE BILIARY EPITHELIAL CELLS PROMOTES PORTAL FIBROSIS IN CONGENITAL HEPATIC FIBROSIS. Hepatol. Baltim. Md, vol.63, pp.965-982, 2016.
Inflammation and myeloproliferative neoplasms, J. Autoimmun, vol.85, pp.58-63, 2017. ,
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata, JCI Insight, vol.1, 2016. ,
Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: Implications for biologics-small molecule drug interactions, Expert Opin. Drug Metab. Toxicol, vol.13, pp.605-616, 2017. ,
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects, Drugs, 2019. ,
C-reactive protein: Ligands, receptors and role in inflammation, Clin. Immunol, vol.117, pp.104-111, 2005. ,
, Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis, 2018.
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice, Blood, vol.128, pp.60-71, 2016. ,
,
, Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice
Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes, Front. Immunol, vol.9, 2018. ,
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial, Br. J. Haematol, vol.170, pp.29-39, 2015. ,
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, vol.388, p.394, 1997. ,
Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain, Genes Dev, vol.20, pp.3372-3381, 2006. ,
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF), Br. J. Haematol, vol.176, pp.76-85, 2017. ,
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease, Hepatology, vol.49, pp.1877-1887, 2009. ,
Monomeric C-reactive protein modulates classic complement activation on necrotic cells, FASEB J, vol.25, pp.4198-4210, 2011. ,
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression, Int. J. Cancer, 2019. ,
C-Reactive Protein Mediates Protection from Lipopolysaccharide Through Interactions With Fc?R, J. Immunol, vol.169, pp.7019-7025, 2002. ,
Regulation of Cytochrome P450 by Inflammatory Mediators: Why and How?, Drug Metab. Dispos, vol.29, pp.207-212, 2001. ,
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metab. Dispos, vol.36, pp.205-216, 2008. ,
Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol, vol.8, pp.958-969, 2008. ,
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice, J. Hepatol, vol.66, pp.1037-1046, 2017. ,
JAK inhibitors in 2019, synthetic review in 10 points, Eur. J. Intern. Med, 2019. ,
Macrophage Polarization, Annu. Rev. Physiol, vol.79, pp.541-566, 2017. ,
Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model, Transpl. Immunol, 2017. ,
Structure of the Unphosphorylated STAT5a Dimer, J. Biol. Chem, vol.280, pp.40782-40787, 2005. ,
, Ruxolitinib for Therapy of Graft-versus-Host Disease, 2019.
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death, Nat. Rev. Mol. Cell Biol, vol.14, pp.727-736, 2013. ,
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review, Dermatol. Ther, vol.0, p.13053, 2019. ,
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation, Breast Cancer Res. Treat, vol.170, pp.547-557, 2018. ,
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases, Br. J. Haematol, vol.130, pp.709-715, 2005. ,
Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA, Blood, vol.62, pp.832-845, 1983. ,
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis, Br. J. Dermatol, vol.173, pp.767-776, 2015. ,
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms, Br. J. Haematol, vol.169, pp.824-833, 2015. ,
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs, Lung Cancer Amst. Neth, vol.134, pp.46-51, 2019. ,
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study, Lancet Oncol, vol.18, pp.88-99, 2017. ,
,
, JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models, Cancer Gene Ther
C-reactive protein: a critical update, J. Clin. Invest, vol.111, pp.1805-1812, 2003. ,
JAK inhibitors for alopecia areata: a systematic review and meta-analysis, J. Eur. Acad. Dermatol. Venereol. JEADV, 2019. ,
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms, Am. J. Hematol, vol.92, pp.187-195, 2017. ,
Mechanisms of type-I-and type-II-interferon-mediated signalling, Nat. Rev. Immunol, vol.5, p.375, 2005. ,
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene, Science, vol.282, pp.2085-2088, 1998. ,
Real Time Analysis of STAT3 Nucleocytoplasmic Shuttling, J. Biol. Chem, vol.279, pp.15114-15123, 2004. ,
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor, Br. J. Dermatol, vol.173, pp.989-997, 2015. ,
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood, vol.115, pp.3109-3117, 2010. ,
STATs get their move on, JAK-STAT, vol.2, 2013. ,
Role of interleukin-1? during pain and inflammation, Brain Res. Rev, vol.60, pp.57-64, 2009. ,
Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention, Circulation, vol.107, pp.363-369, 2003. ,
The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation, Clin. Pharmacol. Ther, vol.102, pp.591-598, 2017. ,
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib, J. Am. Acad. Dermatol, vol.76, pp.1054-1060, 2017. ,
The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction, Proc. Natl. Acad. Sci. U. S. A, vol.103, pp.6299-6304, 2006. ,
, , 2015.
, HepaRG Cells as Human-Relevant In Vitro Model to Study the Effects of Inflammatory Stimuli on Cytochrome P450 Isoenzymes, Drug Metab. Dispos, vol.43, pp.119-125
, , 2016.
, The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK, Leukemia, vol.30, pp.2119-2123
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis, Blood Coagul. Fibrinolysis, vol.27, pp.648-652, 2016. ,
The pro-and antiinflammatory properties of the cytokine interleukin-6, Biochim. Biophys. Acta BBA -Mol. Cell Res, vol.1813, pp.878-888, 2011. ,
Physiological effects of modulating the interleukin-6 axis, Rheumatology, vol.57, pp.43-50, 2018. ,
Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis, Clin. Pharmacol. Ther, vol.89, pp.735-740, 2011. ,
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Res, vol.75, pp.2187-2199, 2015. ,
The roles of ubiquitination in extrinsic cell death pathways and its implications for therapeutics, Biochem. Pharmacol, vol.162, pp.21-40, 2019. ,
Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity, Food Chem. Toxicol, vol.96, pp.290-301, 2016. ,
Macrophage plasticity, polarization, and function in health and disease, J. Cell. Physiol, vol.233, pp.6425-6440, 2018. ,
Hepatic TLR4 signaling in obese NAFLD, Am. J. Physiol. -Gastrointest. Liver Physiol, vol.309, pp.270-278, 2015. ,
Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor ?B and Mitogen-Activated Protein Kinase Pathways, Front. Immunol, vol.9, 2018. ,
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers, J. Clin. Pharmacol, vol.51, pp.1644-1654, 2011. ,
,
, MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4, J. Exp. Med, vol.189, pp.1777-1782
Regulation of JAK-STAT signalling in the immune system, Nat. Rev. Immunol, vol.3, pp.900-911, 2003. ,
The IL-1 family: regulators of immunity, Nat. Rev. Immunol, vol.10, pp.89-102, 2010. ,
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, Ann. Rheum. Dis, vol.72, pp.482-492, 2013. ,
Role of C-Reactive Protein at Sites of Inflammation and Infection, Front. Immunol, vol.9, 2018. ,
Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date, Mol. J. Synth. Chem. Nat. Prod. Chem, vol.22, 2017. ,
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms, J. Clin. Invest, vol.130, pp.1596-1611, 2019. ,
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer, NPJ Breast Cancer, vol.4, 2018. ,
Gut-Liver Axis and Sensing Microbes, Dig. Dis. Basel Switz, vol.28, pp.737-744, 2011. ,
The Biology and Medical Implications of Interleukin-6, Cancer Immunol. Res, vol.2, pp.288-294, 2014. ,
Human pro-Tumor Necrosis Factor Is a Homotrimer, Biochemistry, vol.35, pp.8216-8225, 1996. ,
, , 2011.
, Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study, J. Clin. Oncol, vol.29, pp.1356-1363
Janus Kinase Inhibitors, Encyclopedia of Inflammatory Diseases, M. Parnham, pp.1-5, 2016. ,
, Membrane transporters in drug development, The International Transporter Consortium, vol.9, pp.215-236, 2010.
Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum, J. Exp. Med, vol.164, pp.777-793, 1986. ,
The role of C-reactive protein in innate and acquired inflammation: new perspectives, Inflamm. Cell Signal, vol.3, 2016. ,
Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis, Am. J. Hematol, vol.87, pp.1003-1005, 2012. ,
Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N. Engl. J. Med, vol.372, pp.1670-1671, 2015. ,
Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-? or Interleukin-6, Drug Metab. Dispos, vol.37, pp.685-693, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00673249
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation, Am. J. Physiol. Regul. Integr. Comp. Physiol, vol.285, pp.1257-1258, 2003. ,
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, N. Engl. J. Med, vol.363, pp.1117-1127, 2010. ,
A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, N. Engl. J. Med, vol.366, pp.799-807, 2012. ,
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial, Haematologica, vol.101, pp.821-829, 2016. ,
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebocontrolled, phase 3 COMFORT-I trial, J. Hematol. Oncol.J Hematol Oncol, vol.10, 2017. ,
Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results, Am. J. Hematol, vol.94, pp.319-326, 2019. ,
Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4, Proc. Natl. Acad. Sci. U. S. A, vol.98, p.12156, 2001. ,
TAK1 is a ubiquitin-dependent kinase of MKK and IKK, Nature, vol.412, p.346, 2001. ,
Type I Interferon Receptors: Biochemistry and Biological Functions, J. Biol. Chem, vol.282, 2007. ,
Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages, J. Exp. Med, vol.170, pp.1231-1241, 1989. ,
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein, Science, vol.249, pp.1431-1433, 1990. ,
Endogenous toll-like receptor ligands and their biological significance, J. Cell. Mol. Med, vol.14, pp.2592-2603, 2010. ,
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol. Ther, vol.138, pp.103-141, 2013. ,
Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey, Leukemia, vol.29, pp.2062-2068, 2015. ,
STAT3 Participates in Transcriptional Activation of the C-reactive Protein Gene by Interleukin-6, J. Biol. Chem, vol.271, pp.9503-9509, 1996. ,
JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment, Ann. Rheum. Dis, vol.76, pp.1467-1475, 2017. ,
, , 2014.
, Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348), Leukemia, vol.28, pp.404-407
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach, J. Clin. Pharmacol, vol.55, pp.1386-1394, 2015. ,
The JAK1/2 inhibitor ruxolitinib represses LPS-mediated expression of acute phase proteins in cultured human hepatocytes, Activités scientifiques et enseignement Publications 1 -Febvre, 2019. ,
, Inflammation Research
, Risque incendie, biologique et chimique » -09 Novembre 2016 -Rennes 4 -« Manipulation des sources radioactives non scellées » -09 Novembre 2016 -Rennes Enseignement : Missions d'enseignement
, UE Histologie -IUT 1ere année -Université Clermont Auvergne -27h TP -Semestre 2 2018 2 -UE Microenvironnement Cellulaire Normal et Pathologique -Master 2 Biologie Moléculaire et Cellulaire -Université de Rennes 1 -1h30 CM, p.1, 2017.
apoptose et vieillissement -Licence 3 Biologie Cellulaire, Génétique, Microbiologie, Physiologie animale -Université de Rennes 1 -28h TP (dont 22h en anglais) -Semestre, pp.24-25, 2016. ,
, -UE Organisation fonctionnelle de la cellule -Licence 2 Sciences Moléculaires et Cellulaires -Université de Rennes 1 -12h TP -Semestre, 2017.
, -Présentation des résultats au cours de réunions de travail dans le cadre du projet HII-GO -Cancéropôle Grand-Ouest -Nantes -31 Mars 2016 et 8 Juin 2017 + 2 Visioconférences, 2016.
, 2 -Participation aux Journées Portes Ouvertes de l'Université de Rennes 1 en 2016 et 2017 -Organisation des visites des salles de TP